Haryana govt administers COVAXIN to 3 volunteers, 'no adverse effects noted' says Anil Vij

Confirming commencement of first phase of human trials for India's indigeus COVID-19 vaccine - COVAXIN, Haryana Health Minister Anil Vij on Friday, said three participants were ministered vaccine at  Post-Gruate Institute of Medical Sciences (PGI) Rohtak. He ded that all subjects have tolerated vaccine well with verse effects. ICMR has informed that approximately 1000 human volunteers are under clinical study in various test sites for two vaccine contentders - COVAXIN (ICMR-NIC with Bharat Biotech) and  ZyCov-D (Zydus Cilla).

Rajasthan Govt Crisis LIVE Updates: HC journs Pilot plea; action on MLAs till Tuesday

Haryana's test subjects responding well: Vij 

Bharat Biotech begins first phase of clinical trials for India's Covid vaccine 'Covaxin'

Human trials for COVAXIN & ZyCov-D begin

trials phase-1 & 2 have kicked-off combinedly in ICMR shortlisted locations - New Delhi, Patna, Chennai, Kanpur, Gorakhpur, Goa, Bhubaneswar, Rohtak, Hyderab and Visakhapatnam among ors. Volunteers across country are undergoing assessment for all health parameters such as liver functions and infections and to check if y have COVID-19 infections as trials cant be done on COVID infected people or even asymptomatic patients. After assessment, subjects would be cleared for small doses of one of two vaccines and results will be studied.

Human trials for COVID vaccine kick-started with 1000 human volunteers: ICMR

ICMR fast-tracks Covaxin trials

On July 3, ICMR fast-tracked Bharat Biotech India Ltd (BBIL)'s Coronavirus (COVID-19) vaccine - Covaxin & Zydus Cilla's ZyCov-D's clinical trials. In an official statement, ICMR Director General Balram Bhargava stated that ICMR aims to launch indigeus COVID-19 vaccine by August 15. Covaxin and  ZyCov-D were approved by DCGI recently to proceed to clinical trials after it showed promise in its pre-clinical data.

country's apex medical body has selected 12 institutes across country and has vised m to expedite approvals and complete recruiting for trials by 7 July. "Kindly te that n-compliance will be viewed seriously," letter states, ding that institutions must treat this project on highest priority and meet given timelines without any lapse. Apart from Odisha, institutes selected for clinical trial are located in Visakhapatnam, Rohtak (Haryana), New Delhi, Patna, Belgaum (Karnataka), Nagpur (Maharashtra), Gorakhpur, Kanpur (UP), Kattankulathur (Tamil Nu), Hyderab, Arya Nagar and Goa.

Centre reveals 'COVID-19 vaccine expected only by early next year' to parliamentary panel

Scientists question 'rushed vaccine' deline

Reacting to ICMR letter, several experts h raised fears that its safety and efficacy could be compromised. Moreover, scientists have disapproved strict and 'nearly impossible' timeline set by ICMR with an aim to launch vaccine by August 15. ICMR has defended its move stating that y are committed to treating public safety as topmost priority and said that process followed by apex medical body is in 'accordance with globally accepted rms to fast-track vaccine development'. Moreover, Centre has informed a parliamentary panel that a vaccine for COVID-19 is expected only by early next year.